Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Clinical and Experimental Pathology

• Publication date

  2014-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 25337277PMCID PMC4203248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013influential reference
• Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations

  2009cited by this paper
• Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma

  2009cited by this paper
• Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

  2009influential reference
• A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility

  2007influential reference
• Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer

  2007cited by this paper
• HER2 testing in breast cancer: NCCN Task Force report and recommendations.

  2006cited by this paper
• HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists.

  2006cited by this paper
• Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

  2005cited by this paper
• HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques

  2005cited by this paper
• HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.

  2005cited by this paper
• Histopathologic Characteristics Predicting HER‐2/neu Amplification in Breast Cancer

  2005cited by this paper
• Real‐time reverse transcription‐PCR and fluorescence in‐situ hybridization are complementary to understand the mechanisms involved in HER‐2/neu overexpression in human breast carcinomas

  2005cited by this paper
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cited by this paper
• Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer

  2005cited by this paper
• HER-2 testing in breast cancer using parallel tissue-based methods.

  2004cited by this paper
• Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?

  2004cited by this paper
• Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.

  2003cited by this paper
• Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status

  2002cited by this paper
• HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

  2002cited by this paper
• Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer

  2002cited by this paper
• Detection of HER‐2/neu (c‐erb B‐2) DNA amplification in primary breast carcinoma

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu Polysomy

  2001cited by this paper
• Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.

  2001cited by this paper
• Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

  2001influential reference
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.

  2000cited by this paper
• HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• The value of histological grade in breast cancer experience from a large study with a long term follow up

  1991cited by this paper

• 225Ac-NOTA-trastuzumab human dosimetry using inter-radionuclide and biological half-life based allometric extrapolation method

  2026cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• HER2-ultralow Breast Cancer: Incidence, Clinicopathologic Features and Need for Refined Scoring System.

  2025cites this paper
• Her-2/neu gene amplification and its correlation with other prognostic factors in Iranian breast cancer patients

  2024cites this paper
• Aneuploidy as a driver of human cancer

  2024cites this paper
• Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

  2023cites this paper
• Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy

  2023cites this paper
• Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization

  2023cites this paper
• Breast tumor IGF1R regulates cell adhesion and metastasis: alignment of mouse single cell and human breast cancer transcriptomics

  2022cites this paper
• MUC1 triggers lineage plasticity of Her2 positive mammary tumors

  2022cites this paper
• Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate

  2022cites this paper
• Breast tumor Insulin-like growth factor receptor regulates cell adhesion and metastasis: Alignment of mouse single cell and human breast cancer transcriptomics

  2021cites this paper
• Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review

  2020cites this paper
• Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach

  2020cites this paper
• Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

  2019cites this paper
• STATISTICAL ANALYSIS OF 100 BREAST CANCER CASES WITH EVALUATION OF HER2/NEU STATUS IMMUNOHISTOCHEMISTRY CORRELATION WITH GENE AMPLIFICATION BY FLUORESCENCE IN SITU HYBRIDIZATION ASSAY

  2018cites this paper
• her2 breast cancer group in morocco a pathological and statistical study

  2018cites this paper
• HER2‐Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights

  2018cites this paper
• Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization

  2017cites this paper
• Small sentinel node metastases in breast cancer : displaced epithelium or malignant cells

  2017influential citation
• The role of Pim-1 in breast cancer metastasis

  2017cites this paper
• Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors

  2017cites this paper
• DUODENAL AND COLONIC METASTASIS AS THE FIRST MANIFESTATION OF A MULTICENTRIC INVASIVE LOBULAR CARCINOMA OF THE BREAST

  2016cites this paper
• Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

  2016cites this paper
• Development of nanoparticle platform for therapeutic siRNA and drug delivery to breast cancer

  2015cites this paper